Antibiotic Awareness Week 2017
Discover more about our efforts to raise awareness on the global threat of antibiotic resistance
Our week will coincide with national and international campaigns, including WHO World Antibiotic Awareness Week, The ECDC’s European Antibiotics Awareness Day and the USCDC’s renamed Antibiotic Awareness Week, all of which take place November 13-19, 2017.
During this week, we will highlight the huge global health issue of Antibiotic Resistance to our customers, employees and the general public. We will raise awareness that rapid diagnostics can guide targeted treatment decisions, thereby allowing healthcare professionals to make the right treatment decisions, reducing inappropriate antimicrobial use and in the long term reducing the spread of resistance.
Our activities for the week will include:
- Utilising our website and our global sales network to raise awareness
- Distribute tools and guidelines to healthcare professionals and facilities
- Deliver presentations to interested parties
- Educate our employees on the crisis through our internal communications network
- Encourage people to sign an Antibiotic Awareness Pledge committing to fighting resistance
Antibiotic resistance is a huge global health issue and contributes significantly to patient mortality and rising healthcare costs across the world. Approximately 50% of antibiotic prescriptions are unnecessary, for example, the majority of ARTI (Acute Respiratory Tract Infections) are viral and hence not susceptible to antibiotic therapy. Treating viral infections with antibiotics is counter-productive, exposing bacteria to antibiotics unnecessarily and increasing the likelihood of developing resistance.
There is a clear need to differentiate between viral and bacterial infections, as well as identifying quickly and accurately the nature of the pathogen in order to prescribe the most appropriate treatment with the optimal clinical result. The common practice of prescribing broad spectrum antibiotics in place of targeted narrow spectrum therapy is a major factor in the growth of resistant bacteria species and the spread of Healthcare Associated Infections (HAIs) such as MRSA and Clostridium difficile.
“Test Target Treat” is designed to raise awareness that rapid diagnostics can allow targeted treatment decisions faster than traditional methods. This enables healthcare professionals to make the right treatment decisions, reducing inappropriate antimicrobial use and in the long term reducing the spread of resistance.
The companies, websites, products and services, and brands referenced and linked to/from this website are not sponsored or endorsed by, or otherwise affiliated with, Alere or TestTargetTreat.com. The third-party products and services referenced and linked to/ from this website are included for informational purposes only, and have not been tested or approved by Alere or TestTargetTreat.com. Neither Alere nor TestTargetTreat.com makes any representations or warranties regarding third-party products or services, and shall not be liable for any claims arising from those products or services or your use thereof.